Market Place
Sourcing Support
MaaT Pharma Publishes Retrospective Data on GvHD in BMT Journal
01 Apr 2026 //
BUSINESSWIRE
MaaT Pharma Presents Final ARES Phase 3 Data at EBMT Meeting
23 Mar 2026 //
PHARMIWEB
Maat Pharma To Present Four Abstracts At The 52Nd European Bone
09 Mar 2026 //
BUSSINESSWIRE
MaaT Pharma Gets €37.5M EIB Loan for Hemato-Oncology
28 Jul 2025 //
BUSINESSWIRE
MaaT Pharma Updates Business and Key Milestones for 2025
19 Jun 2025 //
BUSINESSWIRE
MaaT Pharma Presents Positive Data for Xervyteg at EHA Congress
13 Jun 2025 //
BUSINESSWIRE
MaaT Pharma Shows MaaT034`s Immune Activation at AACR Meeting
28 Apr 2025 //
BUSINESSWIRE
MaaT Pharma`s Stock Covered by H.C. Wainwright & Co.
07 Apr 2025 //
BUSINESSWIRE
MaaT Pharma touts Phase 3 efficacy of graft-versus-host disease treatment
09 Jan 2025 //
ENDPTS
MaaT Pharma Announces Positive DSMB Review For MaaT033 Phase 2 Trial
02 Jul 2024 //
BUSINESSWIRE
MaaT Pharma Coverage Initiated with Buy Rating, EUR 16 Target Price by Stifel
25 Jun 2024 //
BUSINESSWIRE
MaaT Pharma appoints Gianfranco Pittari, M.D., Ph.D., as Chief Medical Officer.
24 Jun 2024 //
BUSINESSWIRE
MaaT Pharma Business Update And 2024 Milestones
07 May 2024 //
BUSINESSWIRE
Mustang Bio to lay off workers; MaaT`s new data for microbiome therapy
15 Apr 2024 //
ENDPTS
MaaT Pharma Presents Promising Preclinical Data at AACR for MaaT034
08 Apr 2024 //
BUSINESSWIRE
MaaT Pharma Announces Initiation of Coverage of its Stock by Gilbert Dupont
05 Apr 2024 //
BUSINESSWIRE
MaaT Pharma Announces 2023 Annual Results and Provides a Business Overview
28 Mar 2024 //
BUSINESSWIRE
MaaT Strengthens Executive Team Appointing Chriqui as Chief Business Officer
21 Mar 2024 //
BUSINESSWIRE
MaaT Pharma To Present New Preclinical Data at AACR for MaaT034 Aiming
19 Mar 2024 //
BUSINESSWIRE
MaaT Pharma Provides Third Quarter 2023 Reports Financial Results
09 Nov 2023 //
BUSINESSWIRE
MaaT Pharma to Present Preclinical Data at SITC on MaaT034
31 Oct 2023 //
BUSINESSWIRE
MaaT Pharma Announces Poster Presentations at the 38th Annual Meeting
27 Sep 2023 //
BUSINESSWIRE
MaaT Pharma Publishes its Half Year 2023 Results and Provides a Business Update
26 Sep 2023 //
BUSINESSWIRE
MaaT &Skyepharma Complete Construction of Largest Manufacturing
12 Sep 2023 //
BUSINESSWIRE
MaaT Pharma Provides Q2 2023 Business Update and Reports Financial Results
27 Jul 2023 //
BUSINESSWIRE
MaaT Pharma Joins Microbiome Therapeutics Innovation Group
20 Jul 2023 //
BUSINESSWIRE
FDA lifts nearly two-year hold on MaaT`s microbiome therapy, opens door to PIII
25 Apr 2023 //
ENDPTS
MaaT Pharma Announces U.S. FDA Lifts Clinical Hold on Phase 3 Inda for MaaT013
24 Apr 2023 //
BUSINESSWIRE
MaaT Pharma to Present Data for MaaT013 and MaaT033 at EBMT Annual Meeting
11 Apr 2023 //
BUSINESSWIRE
MaaT Pharma Announces 2022 Annual Results and Provides a Business Overview
30 Mar 2023 //
BUSINESSWIRE
MaaT Pharma Receives U.S. FDA Response for Investigational NDA for MaaT013
03 Feb 2023 //
BUSINESSWIRE
After 18-month hold, MaaT sees end to impasse with FDA
03 Feb 2023 //
FIERCE BIOTECH
MaaT Provides Corporate Update and Highlights Key Expected Milestones in 2023
24 Jan 2023 //
BUSINESSWIRE
MaaT Pharma Presents Promising Results from Phase 1b Trial with MaaT033
11 Dec 2022 //
BUSINESSWIRE
MaaT Pharma Presents Compelling Consolidated MaaT013 Clinical Data
10 Dec 2022 //
BUSINESSWIRE
MaaT Pharma To Webcast Investor Meeting in Conjunction with ASH 2022 Conference
29 Nov 2022 //
BUSINESSWIRE
MaaT Pharma Reports Cash and Revenues for Third Quarter 2022
08 Nov 2022 //
BUSINESSWIRE
MaaT Announces Participation in Scientific and Investor Conferences in November
07 Nov 2022 //
BUSINESSWIRE
MaaT Pharma AnnouncesPresentations at the 64th ASH Annual Meeting
03 Nov 2022 //
BUSINESSWIRE
MaaT Pharma Appoints Nathalie Corvaïa as CSO and Strengthens its R&Dgy
04 Oct 2022 //
BUSINESSWIRE
MaaT Pharma Appoints Nathalie Corvaïa as Chief Scientific Officer
04 Oct 2022 //
BUSINESSWIRE
MaaT Pharma Publishes its Half Year Results Business Update
29 Sep 2022 //
BUSINESSWIRE
MaaT Announces Participation in Three Upcoming Investor Conferences in September
08 Sep 2022 //
BUSINESSWIRE
1 year into clinical hold, FDA has questions about `pooled` microbiome therapy
11 Aug 2022 //
ENDPOINTS NEWS
FDA declines to free MaaT`s microbiome drug from clinical hold after a year
11 Aug 2022 //
FIERCE BIOTECH
MaaT Pharma Reports Cash and Revenues for Second Quarter 2022
28 Jul 2022 //
BUSINESSWIRE
MaaT Pharma reports positive data from Phase Ib blood cancer trial
03 Jun 2022 //
CLINICALTRIALSARENA
MaaT Pharma Confirms +ve Results from PIb CIMON Study of MaaT033
02 Jun 2022 //
BUSINESSWIRE
MaaT Pharma to Host First Virtual R&D Day on June 7th, 2022
24 May 2022 //
BUSINESSWIRE
MaaT Pharma Reports Cash and Revenues for First Quarter 2022
05 May 2022 //
BUSINESSWIRE
INRAE and MaaT Pharma to develop Drug-Candidate MaaT013 into PIII Trial
20 Apr 2022 //
BUSINESSWIRE
MaaT Pharma Publishes its 2021 Annual Results & Business Overview
14 Apr 2022 //
PRESS RELEASE
MaaT Pharma Initiates Phase 2a Trial of MaaT013 + Immune Checkpoint Inhibitors
07 Apr 2022 //
BUSINESSWIRE
MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights
04 Apr 2022 //
BUSINESSWIRE
MaaT Pharma Announces First Patient Dosed in Phase 3 ‘ARES’ Trial for MaaT013
28 Mar 2022 //
BUSINESSWIRE
MaaT Pharma Implements Liquidity Contract with Kepler Cheuvreux
21 Mar 2022 //
BUSINESSWIRE
MaaT Pharma to Present Promising Data for MaaT013 at 48th EBMT
17 Mar 2022 //
BUSINESSWIRE
MaaT Pharma, Skyepharma Partner to Establish cGMP Mfg
08 Feb 2022 //
PRESS RELEASE
MaaT Announces Positive Interim Engraftment Data for Oral Formulation MaaT033
24 Jan 2022 //
BUSINESSWIRE
MaaT Pharma Provides Business Objectives and Expected Milestones for 2022
17 Jan 2022 //
BUSINESSWIRE
